Abstract
Gold coated magnetite nanoparticles were prepared and coated with ranibizumab as an ocular drug delivery system. The surface morphologies of the nanoparticles were determined by Scanning Electron Microscopy (SEM). The size and surface charge were determined by using the dynamic light scattering (DLS) technique. Crystallographic properties of the gold coated Fe3O4 nanoparticles were recorded on X-ray diffractometer (XRD) the XRD pattern of nanoparticlees were shown to have uniqe Fe3O4 and gold peaks. Conjugation of ranibizumab onto nanoparticles was achieved using the physical adsorption method. The amount of ranibizumab on the surface of the nanoparticles was determined by thermogravimetric analysis (TGA). In the in vitro release studies performed using UV spectroscopy; it was found that almost 60% of antibodies were released within the first 30 minutes. Antibody activity after release studies was also proved with ELISA. Non-toxicity of gold coated Fe3O4 particles were proved with MTT. Results of the studies, showed that the antibody conjugated magnetic nanoparticle system could be a potential treatment system for ocular diseases.
Highlights
Age-related Macular Degeneration (AMD) is the major cause of irreversible vission loss in the world in people 50 years of age or elderly population in the world (Eter et al, 2006)
AMD can be present in two forms, atrophic or choroidal neovascular AMD (CNV) (Van Leeuwen et al, 2003)
Photodynamic therapy (PDT) with verteporfin has been used in the 1990s for AMD treatment
Summary
Age-related Macular Degeneration (AMD) is the major cause of irreversible vission loss in the world in people 50 years of age or elderly population in the world (Eter et al, 2006). In the 1980s laser photocoagulation was used for the treatment of neovascular AMD. Treatment with laser was effective in reducing long-term severe visual loss, it was limited by lack of vision gain and high recurrence rates (50%) (Lim et al, 2012). After accumulation of verteporfin in neovascular membranes, the dye is activated with infrared light. This process generates oxygen-free radicals that damage the endothelium, promoting closure of newly formed vessels (Lim et al, 2012; Schmidt-Erfurth, Hasan, 2000). Intravitreal injections limit therapy to the eye, avoiding systemic administration and possibly reducing the incidence of systemic adverse effects (Jager et al, 2008)
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call